Solid Biosciences (SLDB) EBITDA Margin: 2022-2024
Historic EBITDA Margin for Solid Biosciences (SLDB) over the last 2 years, with Dec 2024 value amounting to 53,194.67%.
- Solid Biosciences' EBITDA Margin rose 3115011.00% to 53,194.67% in Q4 2024 from the same period last year, while for Dec 2024 it was 38,155.29%, marking a year-over-year increase of 1440769.00%. This contributed to the annual value of 38,155.29% for FY2024, which is 1446166.00% up from last year.
- Per Solid Biosciences' latest filing, its EBITDA Margin stood at 53,194.67% for Q4 2024, which was up 23.98% from 42,904.88% recorded in Q3 2024.
- Over the past 5 years, Solid Biosciences' EBITDA Margin peaked at 53,194.67% during Q4 2024, and registered a low of -1,318.03% during Q2 2022.
- Moreover, its 3-year median value for EBITDA Margin was 26,471.07% (2023), whereas its average is 27,682.08%.
- Data for Solid Biosciences' EBITDA Margin shows a peak YoY surged of 3,115,011bps (in 2024) over the last 5 years.
- Quarterly analysis of 3 years shows Solid Biosciences' EBITDA Margin stood at -1,318.03% in 2022, then soared by 2,550,091bps to 22,044.55% in 2023, then surged by 3,115,011bps to 53,194.67% in 2024.
- Its last three reported values are 53,194.67% in Q4 2024, 42,904.88% for Q3 2024, and 31,577.27% during Q2 2024.